



2027 – 2030

STRATEGIC PLAN

ACKNOWLEDGEMENT OF COUNTRY

ALK Positive Australia acknowledges the Traditional Custodians of the lands on which we live, work and connect with our community across Australia. We pay our respects to Elders past and present, and recognise their continuing connection to land, culture and community.

This Strategic Plan 2027-2030 was developed in consultation with the ALK Positive Australia membership and endorsed by the Executive Committee on 8 October 2026



JON GRAFTDYK OAM, PHD

*Chairperson
ALK Positive Australia Inc*

ALK Positive Australia Inc. ABN 75665458254. Registered charity with the Australian Charities and Not-for-profits Commission (ACNC).



Strategic Plan 2027-2030
Adopted 8 October 2026 | Version 1.0

GLOSSARY

ACNC – Australian Charities and Not-for-profits Commission

MRFF – Medical Research Future Fund

MSAC – Medical Services Advisory Committee

NHMRC – National Health and Medical Research Council

PBAC – Pharmaceutical Benefits Advisory Committee

PBS – Pharmaceutical Benefits Scheme

TGA – Therapeutic Goods Administration

TOGA – Thoracic Oncology Group of Australasia

TABLE OF CONTENTS

BACKGROUND	4
WHO WE ARE, WHAT WE DO, WHAT GUIDES US	5
MEMBER CONSULTATION	6
WHAT WE HEARD	8
WHAT IS IMPORTANT TO OUR MEMBERS?	9
PILLAR 1: RESEARCH & INNOVATION	12
PILLAR 2: ADVOCACY & POLICY	15
PILLAR 3: AWARENESS	16
PILLAR 4: COMMUNITY CONNECTION & SUPPORT	17
IMPLEMENTATION PLAN	18
CLOSING STATEMENT	19

BACKGROUND


ALK Positive Australia Inc was born from a simple question. In June 2022, shortly after being diagnosed with ALK+ lung cancer, Jon Graftdyk asked members of the 'ALK and ROS1 Cancer - Australia & New Zealand' Facebook support group page how Australians could directly donate to ALK+ research through a dedicated Australian charity. While opportunities existed to donate to broader Australian lung cancer organisations and ALK Positive international initiatives, there was no Australian charity focused specifically on ALK+ cancer and no mechanism to ensure donations raised in Australia were directed to ALK+ cancer research.

The question resonated with others in the community, including Graham Hall who shared a vision for creating an Australian organisation dedicated to the needs of ALK+ cancer patients and their families. With encouragement from the broader global ALK community, including discussions with leaders from ALK Positive Inc. in the United States, the idea quickly evolved into a commitment to establish a patient-led Australian charity.

Over the following months, a small group of patients and carers came together to turn that vision into reality. Founding members Ellie Anzalchi, Jon Graftdyk and Graham Hall, together with Chris Bailey, Amanda Nickells and Alison Hall, each contributed their time, expertise, financial support and determination to establish the organisation. Jon coordinated much of the work involved in establishing the charity and navigating the regulatory requirements, while Chris drew on his legal expertise to establish the incorporated association. Graham secured funding through his IASLC Patient Advocate Educational Award to develop the organisation's first website, creating an important platform to connect with ALK+ patients and families across Australia and share information, support and opportunities for involvement.

Together, these contributions laid the foundations for a sustainable, patient-led charity. ALK Positive Australia was incorporated in October 2022 and registered with the Australian Charities and Not-for-profits Commission later that month.

Since its establishment, the organisation has remained true to its founding purpose: a patient-led charity dedicated to supporting Australians affected by ALK+ cancer through advocacy, education, and awareness, while raising funds that directly support ALK+ cancer research. Through the collective efforts of patients, care partners, clinicians, researchers, and supporters, we continue working toward better outcomes and longer lives for everyone impacted by ALK+ cancer.



REMEMBERING ELLIE ANZALCHI

Ellie Anzalchi was one of the founding members of ALK Positive Australia and made an important contribution to establishing the organisation. Her energy, enthusiasm, generosity and determination helped shape the patient-led community we are today. Although Ellie is no longer with us, we recognise and remain grateful for the contribution she made to ALK Positive Australia and the impact she had on those who worked alongside her.

WHO WE ARE, WHAT WE DO, WHAT GUIDES US?



Why we exist

PURPOSE: To improve the lives, experiences, and outcomes of Australians affected by ALK+ cancer by ensuring their voices are heard, their needs are understood, and advances in research and care translate into meaningful benefits for every person and family impacted by the disease.



What we do

MISSION: To be the leading national voice for Australians affected by ALK+ cancer, advancing better outcomes through advocacy, education, research investment, community connection, precision care navigation, empowerment and evidence-based policy change.



Where we are going

VISION - A future where ALK+cancer is a manageable and ultimately curable disease, and every Australian has equitable access to genomic testing, treatment, support, and person-centred care.



What we value

- **Patient-Led:** We put the lived experiences and voices of people with ALK+ cancer at the heart of everything we do, using evidence to drive advocacy, informed decisions, and meaningful change.
- **Integrity:** We act with transparency, accountability, and honesty, building trust with our members, partners, and community.
- **Compassion:** We lead with empathy, respect, and understanding.
- **Equity:** We champion fair access to evidence-based testing, treatment, information, support, and care for everyone affected by ALK+ cancer.

MEMBER CONSULTATION

Shaping Our Future: Members Voice


On 22 June 2026, ALK Positive Australia emailed all current members inviting them to participate in a survey to help shape the 2027 – 2030 Strategic Plan. The survey sought to ensure that the future priorities, advocacy efforts and resource allocation reflected the needs, perspectives and lived experiences of the ALK Positive Australia community.

A total of **35 responses** were received from the organisation's **86 active members**, representing a response rate of **40.7%**. Members were advised that the survey was confidential, required only 5-6 minutes to complete, and that their **feedback would directly shape the strategic direction of ALK Positive Australia from 2027 – 2030**.

The strong response rate has provided a robust evidence base to directly guide and shape the development of this new Strategic Plan and ensures that the **voices** of people affected by ALK+ cancer **remain central** to the organisation's **future priorities**.

Survey respondents reflected the organisation's core community, with **88.57% living with ALK+ cancer**, while the remaining **11.43%** respondents were family members and caregivers. Responses were received from members Nationally, representing both metropolitan and regional communities, and captured a balanced mix of newer and longer-term members. Together these findings provide confidence that the priorities outlined in this Strategic Plan reflect the diverse experiences and needs of the ALK+ community in Australia.

1 Location



Metropolitan (major city)

71.43%



Rural (small town)

17.14%



Regional (large town/city outside a major city)

11.43%




Remote (isolated area)

0%

7 in 10 respondents lived in a metropolitan (major city) area.

2 Location



WHAT WE HEARD

Responses based on feedback received, demonstrated strong confidence in ALK Positive Australia's current direction and reinforced its value as a trusted source of information, advocacy and community connection. Members recognise the organisation's achievements, particularly in advocacy, while also identifying opportunities to better communicate existing education and research initiatives and further strengthen its impact.

Members were clear about where they want ALK Positive Australia to focus its efforts over the next 3 years.

Open-ended responses revealed several consistent themes. Members want a more **connected national community** with stronger **peer support**, particularly for those newly diagnosed. They also highlighted the need to **raise awareness** of ALK+ cancer among **healthcare professionals** and the **wider community**, **expand research funding** and **clinical trial opportunities**, improve **access to emerging therapies**, and provide more **Australia-specific educational resources**. Respondents also emphasised the importance of stronger communication, member engagement and strategic partnerships to extend the organisation's reach and influence.

Overall, the survey confirms ALK Positive Australia's unique role as the national voice for Australians affected by ALK+ cancer. Members envisage an organisation that continues to lead **advocacy, accelerate research, influence policy, improve equitable access to treatment, reduce stigma through education, and build a connected, informed and empowered community**. These findings provided a clear mandate for the next Strategic Plan and a strong foundation for the organisation's continued growth and impact.




WHAT IS IMPORTANT TO OUR MEMBERS?

Research and innovation emerged as the clear strategic priority for the next three to five years. Members consistently identified **increased investment in ALK+ specific research** as their highest priority, alongside stronger advocacy to improve **equitable access to treatments and ongoing delivery of high-quality education** for patients, carers and healthcare professionals.

Nearly **89% of respondents** identified **increasing funding and support** for ALK Positive cancer **research and innovation** as a priority focus for the next 3 to 5 years. **Over 80%** of respondents also prioritized strengthening **policy and advocacy** for **affordable treatment access**, followed by **63%** who prioritized improving ALK Positive cancer **awareness among healthcare providers and the public**. Less than 18% of respondents ranked addressing equity gaps for underrepresented patient groups as a priority

Response Priorities

Percentage of responses selecting each priority



RESEARCH & INNOVATION

Advance, fund & support ALK+ lung cancer research, to improve survival & quality of life for Australians living with ALK+ lung cancer.



IDENTIFY

ALK Positive Lung Cancer research priorities



COLLABORATE

Nationally & Internationally



FUND

ALK Positive Lung Cancer Research Sustainably



SUPPORT

Consumer Involvement in Research



ADVOCATE

Innovation & Precision Medicine



LEAD

Provide National Leadership

AWARENESS

Enhance ALK Positive Australia's visibility, credibility and influence of ALK+ cancer among the public, healthcare professionals and key stakeholders



INFORM

Raise awareness and build understanding in the broader community.



INFLUENCE

Embed recognition of ALK+ positive lung cancer in policy, funding and health systems.



EQUIP

Increase knowledge and recognition among health professionals



EMPOWER

Ensure everyone feels welcome, heard and supported

ADVOCACY & POLICY

Every Australian with ALK+ cancer has equitable access to the best available care



AWARENESS

Raise awareness and build understanding



ENGAGEMENT

Engage and build trusted partnerships



INFLUENCE

Provide evidence and consumer insights



ACTION

Shape policy, funding and systems



IMPACT

Advance equitable access to care and innovation



CHANGE

A stronger, fairer future for all with ALK-positive lung cancer

COMMUNITY CONNECTION & SUPPORT

No one faces ALK-positive cancer alone



CONNECT

Foster a sense of belonging and peer support.



INFORM

Provide trusted information and practical resources.



ENGAGE

Encourage active involvement and co-creation.



EMPOWER

Support wellbeing, purpose and life goals.



INCLUDE

Ensure everyone feels welcome, heard and supported.

PILLAR 1: RESEARCH & INNOVATION

OUTCOME: Advance, fund & support ALK+ lung cancer research to improve survival and quality of life for Australians living with ALK+ lung cancer.

Key Area of Focus	Actions / Initiatives	How to Measure Success
Research Priorities	<ul style="list-style-type: none"> ALK Positive Lung Cancer Research Priority Framework - Develop a Consumer-Led research framework 	<ul style="list-style-type: none"> Publish, share and promote the National ALK+ lung cancer Priority Framework
	<ul style="list-style-type: none"> Engage and bring together people with lived experience, clinicians, researchers and key stakeholders to identify, the highest-priority research questions that guide future investment in research for <u>ALK+ lung cancer</u>. 	<ul style="list-style-type: none"> Number of stakeholders participating in priority-setting activities. Percentage of projects developed to which align with identified priorities. Percentage of research priorities awarded funding.
	<ul style="list-style-type: none"> Champion the adoption of National ALK Positive Research Priorities by researchers, funders and research organisations. 	<ul style="list-style-type: none"> National research priorities published and reviewed.
Collaborations, Partnerships & Research Ecosystem	<ul style="list-style-type: none"> Develop and strengthen strategic national research collaborations with lung cancer researchers in cancer centres, hospitals, biobanks, Co-operative Clinical Trial Groups, professional societies, government, industry and research organisations to accelerate patient-centred ALK+ lung cancer research in Australia and maximise collaborative funding opportunities. 	<ul style="list-style-type: none"> Increase in the number of national collaborative research partnerships. Increased participation in national collaborative research initiatives. Growth in multi-institution research collaborations.
	<ul style="list-style-type: none"> Facilitate collaborations between Australian and international researchers, clinicians, consumers and industry partners to accelerate research and improve access to emerging therapies and clinical trials. 	<ul style="list-style-type: none"> The number of international research collaborations established Number of Australian researchers or consumers participating in international collaborative research initiatives. The number of international research projects or clinical trials on ALK+ lung cancer, brought to Australia.
	<ul style="list-style-type: none"> Strengthen Australia's ALK+ lung cancer research ecosystem by bringing together consumers, researchers, clinicians, industry, organisations, government and funding partners to accelerate collaboration, influence national research priorities and improve research capacity. 	<ul style="list-style-type: none"> Invitations to participate in national research committees and advisory groups. Number of cross-sector collaborations facilitated. Evidence of influence on national research priorities, funding opportunities or strategic initiatives. Recognition as a trusted national research partner.
	<ul style="list-style-type: none"> Position ALK Positive Australia as Australia's leading charity by convening a National ALK Positive Lung Cancer Research Forum, contributing to national research initiatives, influencing research priorities and strengthening Australia's ALK+ research ecosystem. 	<ul style="list-style-type: none"> National ALK Positive Lung Cancer Research Forum established and delivered.

Research Funding	<ul style="list-style-type: none"> Design a <u>diversified and sustainable</u> research funding model through: grassroots fundraising, community-led events, philanthropy, major giving, corporate partnerships, workplace giving, bequests and recurring donor programs. 	<ul style="list-style-type: none"> Annual increase in money donated for ALK+ lung cancer research Growth in the number of recurring donors, major donors and/or corporate partners. Value of philanthropic funding secured.
	<ul style="list-style-type: none"> Strengthen Australia's ALK+ lung cancer research capability by <u>investing</u> in researchers across all career stages through seed funding and collaborative networks. 	<ul style="list-style-type: none"> Increased number of community fundraising initiatives conducted annually. Value of co-funded research secured. Increasing the number of researchers supported. Increasing the number, type and value of grants awarded. Increasing the number of collaborative research initiatives Competitive grant funding e.g. MRFF, NHMRC
Consumer Capability	1. UNDERSTAND CURRENT INVOLVEMENT Develop a member survey as a <u>baseline measure</u> to identify the current number of members engaged in lung cancer research and the type of activities they are involved with. Review at the conclusion of 2030.	<ul style="list-style-type: none"> Baseline member survey completed Number of members participating in consumer-led research activities.
	2. EMBED FUTURE INVOLVEMENT (ACROSS THE RESEARCH LIFECYCLE) <ul style="list-style-type: none"> Advocate for people with lived experience of ALK+ lung cancer to be embedded as investigators and equal partners across the entire research lifecycle, including; as part of study co-design, in governance committees, implementation, data interpretation and dissemination of research findings. Advocate that external research bodies, institutions and funders remunerate or reimburse consumer representatives for their time and expertise on the same basis as other paid contributors in these processes. 	<ul style="list-style-type: none"> Representation of people with lived experience across research governance, and advisory committees Demonstrated consumer involvement across all stages of research. Sustained and where possible, increased consumer involvement in lung cancer research
	3. BUILD CONSUMER RESEARCH CAPABILITY <ol style="list-style-type: none"> Develop and promote resources that support meaningful consumer involvement in ALK+ research. Help build the capabilities of ALK+ lung cancer community in research by sharing opportunities to undertake research training via IASLC STARS Program, Cancer Council NSW, VCCC and other reputable organisations 	<ul style="list-style-type: none"> Number of consumer resources developed. Eg fact sheets, modules, best practice-consumer engagement links, references etc Sustained and where possible increased member participation and involvement in recognised consumer research training programs.
	4. CREATE OPPORTUNITIES FOR LEADERSHIP <ol style="list-style-type: none"> Encourage members to be included in grant review panels. Share opportunities where involvement of individuals has previously been successful. 	<ul style="list-style-type: none"> Sustained and where possible increased representation of people with lived experience in grant review committees.
	5. RECOGNISE AND DEMONSTRATE IMPACT Increase consumer co-authorship and leadership in research publications and presentations	<ul style="list-style-type: none"> Sustained and where possible increased consumer co-authorship and leadership in research publications and presentations. Evidence of consumer leadership in research outputs and dissemination activities.

Innovation & Precision Medicine	<ul style="list-style-type: none"> Advocate for research that advances precision medicine, genomics, liquid biopsy, ctDNA, artificial intelligence, digital health, patient-reported outcomes and real-world evidence. Support innovative research that improves early detection, treatment selection, monitoring, survivorship and quality of life. Advocate for research that accelerates access to emerging diagnostics and therapies. Foster collaborations that translate scientific innovation into improved patient outcomes. 	<ul style="list-style-type: none"> Number of innovative research projects supported. Number of projects involving emerging technologies. Competitive funding secured for innovative research. Research translated into clinical trials or new models of care. Publications, presentations and innovations arising from supported research.
Research Translation & Impact	<ul style="list-style-type: none"> Engage with researchers to translate research findings into community impact 	<ul style="list-style-type: none"> Number of research projects translated into community resources, advocacy initiatives, future research, or inform clinical practice and future models of care. Number of plain language summaries, educational resources and webinars developed.
	<ul style="list-style-type: none"> Support and influence evidence-informed policy submissions and recommendations that improve access to precision diagnostics, treatments and person-centred care. 	<ul style="list-style-type: none"> Policy submissions or recommendations developed or supported. Members engaged in developing policy submissions and recommendations.
	<ul style="list-style-type: none"> Deliver community research education through webinars to aid understanding and communicate the outcomes of every research investment funded by ALK Positive Australia. 	<ul style="list-style-type: none"> Number of viewers (webinar)
	<ul style="list-style-type: none"> Develop and publish an annual Research Impact Report relevant to the key actions of this strategic plan (in alignment with the annual report) 	<ul style="list-style-type: none"> Including an annual Research Impact Report (as part of the Annual Report) published each year.
National Leadership & Collaboration	<ul style="list-style-type: none"> Position ALK Positive Australia as Australia's leading patient/carer-led partner in ALK+ lung cancer research by influencing national research priorities, establishing strategic collaborations, contributing to advisory committees and continuing to advocate for increased investment in lung cancer research. 	<ul style="list-style-type: none"> Invitations to participate on national committees. Representation on advisory groups. Strategic partnerships. Evidence of influence on national research priorities. Recognition as a trusted national research partner. National ALK Positive Lung Cancer Research Forum delivered.

PILLAR 2: ADVOCACY & POLICY

OUTCOME: Every Australian with ALK+ cancer has equitable access to the best available care.

Key Areas of Focus	Actions/Initiatives	How to Measure Success
Consumer Voice in Policy	<ul style="list-style-type: none"> Collect lived experience through member surveys, interviews and consumer forums to inform advocacy priorities. Ensure consumers are represented on policy, guideline and advisory committees. 	<ul style="list-style-type: none"> Member participation in consultations; consumer representatives appointed; advocacy informed by consumer evidence.
Awareness & Education	<ul style="list-style-type: none"> Raise awareness among policymakers, health care professionals and the public about living with ALK+ cancer, precision medicine and the unique needs of people living with the disease. 	<ul style="list-style-type: none"> Increased awareness of ALK+ cancer among health care professionals. Greater representation of consumer perspectives in policy and clinical discussions.
Medicines, Diagnostics & Reimbursement	<ul style="list-style-type: none"> Advocate to improve the timeliness and access to new ALK therapies 	<ul style="list-style-type: none"> Involvement and engagement in the submission process (include the number if available)
	<ul style="list-style-type: none"> Advocate for equitable access to genomic testing, liquid biopsy, molecular tumour boards and emerging diagnostics. 	<ul style="list-style-type: none"> Submissions, grant applications, and letters of support for diagnostics.
	<ul style="list-style-type: none"> Prepare consumer submissions to PBAC and MSAC, incorporating lived experience and member case studies. 	<ul style="list-style-type: none"> Increase in the number of consumer case studies contributed
Collective Advocacy	<ul style="list-style-type: none"> Collaborate with national and international organisations to deliver coordinated advocacy on shared priorities and amplify the voice of the ALK community. 	<ul style="list-style-type: none"> Joint submissions, research, campaigns and position statements Partnerships established
Influence Government Policy & Investment	<ul style="list-style-type: none"> Respond to Federal and State Government consultations, including MRFF, NHMRC, Cancer Australia and health policy reviews. Advocate for sustained investment in ALK Positive cancer research, precision medicine and consumer-led research. 	<ul style="list-style-type: none"> Number of policy submissions Number of invitations to advisory groups or consultations
Equal Access	<ul style="list-style-type: none"> Ensuring rural, regional, remote and CALD communities have equal access to health technologies, new treatments and clinical trials. 	<ul style="list-style-type: none"> Advocating on behalf of rural, regional, remote and CALD communities for equity of access.
Improve Standards of Care	<ul style="list-style-type: none"> Advocate to clinicians and collect evidence for standards of care including comprehensive genomic testing at diagnosis and progression, routine brain MRI surveillance where clinically appropriate, multidisciplinary care, timely referral pathways and access to clinical trials. 	<ul style="list-style-type: none"> Collecting and presenting evidence to clinicians and policy makers to influence change.
Supportive Care & Survivorship	<ul style="list-style-type: none"> Advocate for equitable access such as psychological support, rehabilitation, fertility preservation, survivorship services, financial counselling, exercise physiology, palliative care and peer support. 	<ul style="list-style-type: none"> Increased services available.

PILLAR 3: AWARENESS

OUTCOME: Enhance the organisation's visibility, credibility and influence of ALK+ cancer among the public, healthcare professionals and key stakeholders

Key Areas of Focus	Actions/Initiatives	How to Measure Success
Public awareness	<ul style="list-style-type: none"> Promote and advertise the existence of ALK Positive Australia Deliver targeted awareness campaigns and communications about ALK+ cancer. Develop and promote accessible, evidence-based information resources Strengthen website, social media and digital communications Participate in relevant national awareness events and campaigns 	<ul style="list-style-type: none"> Number new members Reach, and Interaction/Engagement across communication channels e.g. Website traffic, social media Increased media coverage and public-facing opportunities Growth in community engagement
Health professional awareness	<ul style="list-style-type: none"> Strengthen and formalise referral pathways with treating teams and lung cancer support nurses so people newly diagnosed with ALK+ cancer are connected with ALK Positive Australia at the point of diagnosis. 	<ul style="list-style-type: none"> Number of new members referred through treating centres and specialist nurses.
	<ul style="list-style-type: none"> Presentations, participation and attendance of health care professionals at ALK Positive Australia webinars and community forums. 	<ul style="list-style-type: none"> Number and reach of health professionals engaged
	<ul style="list-style-type: none"> Develop and disseminate relevant consumer resources 	<ul style="list-style-type: none"> Invitations to contribute to professional education, forums or conferences
	<ul style="list-style-type: none"> Build partnerships with professional and clinical organisations 	<ul style="list-style-type: none"> Number of professional partnerships
	<ul style="list-style-type: none"> Share consumer insights and lived experience with health professionals 	<ul style="list-style-type: none"> Members participating in clinical organisations, projects and on committees sharing their lived experience
Community visibility and voice	<ul style="list-style-type: none"> Create opportunities for members to share lived experience 	<ul style="list-style-type: none"> Number and diversity of consumer stories
	<ul style="list-style-type: none"> Support members to participate in advocacy, media and public education 	<ul style="list-style-type: none"> Member participation in awareness, advocacy, media and public education activities
	<ul style="list-style-type: none"> Strengthening engagement of members attending conferences, webinars and professional forums. 	<ul style="list-style-type: none"> Attendance of members at conferences and professional forums

PILLAR 4: COMMUNITY CONNECTION & SUPPORT

OUTCOME: No one faces ALK+ cancer alone

Key Areas of Focus	Actions/Initiatives	How to Measure Success
Peer connection and community support	<ul style="list-style-type: none"> Develop and facilitate opportunities for members to connect with others with ALK+ cancer and carers with lived experience including online and face-to-face connection. Foster a welcoming, inclusive and supportive community environment. Support people living with ALK+ cancer and carers at their most vulnerable times. 	<ul style="list-style-type: none"> Member participation and engagement Member feedback on connection, support and sense of belonging Increase peer connection initiatives
Member engagement and participation	<ul style="list-style-type: none"> Provide opportunities for members to contribute to organisational priorities and initiatives. 	<ul style="list-style-type: none"> Member participation across activities and initiatives
	<ul style="list-style-type: none"> Seek regular member input through surveys, meetings, consultations and community forums. 	<ul style="list-style-type: none"> Response to member feedback. Evidence of decisions or activities informed by member input.
	<ul style="list-style-type: none"> Recognise and celebrate member contributions to the community. 	<ul style="list-style-type: none"> Mentions, nominations or posts celebrating members contributions.
	<ul style="list-style-type: none"> Mentor new members joining the executive and/or sub-committees. 	<ul style="list-style-type: none"> Evidence of mentoring new members.
Information and practical support	<ul style="list-style-type: none"> Provide and connect members to accessible, evidence-based information about ALK+ lung cancer treatment and living with the disease. 	<ul style="list-style-type: none"> Member satisfaction with information and support
	<ul style="list-style-type: none"> Develop resources addressing practical and emotional challenges across the disease journey. 	<ul style="list-style-type: none"> Connecting members to reliable sources of information and relevant services
	<ul style="list-style-type: none"> Identify and respond to emerging information and support needs within the community. 	<ul style="list-style-type: none"> Number of new initiatives developed from members feedback.
Life beyond cancer	<ul style="list-style-type: none"> Focus on survivorship and living well with ALK+ cancer. 	<ul style="list-style-type: none"> Evidence of engagement with survivorship initiatives.
	<ul style="list-style-type: none"> Identify survivorship and living well resources 	<ul style="list-style-type: none"> Providing survivorship resources and services to members.
	<ul style="list-style-type: none"> Identify emerging survivorship needs through member engagement. 	<ul style="list-style-type: none"> Evidence that emerging needs are identified and addressed Promotion of long-term survivorship experiences.
	<ul style="list-style-type: none"> Share experiences and strategies from long-term survivors. 	<ul style="list-style-type: none"> Member feedback on quality, relevance and practical value of support
	<ul style="list-style-type: none"> Advocate for recognition of the longer-term needs of people living with ALK+ cancer 	<ul style="list-style-type: none"> Continue to advocate and build strategic partnerships or initiatives to address long-term ALK+ survivorship needs.

IMPLEMENTATION PLAN

Building our capacity

This plan is deliberately ambitious. Delivering it means growing the people, structures and shared capability behind ALK Positive Australia, drawing more fully on our Executive Committee and our membership, so what today rests on a small number of people, becomes work carried by many. This section sets out how we intend to build on the capacity of ALK Positive Australia as the organisation continues to grow.

Key Areas of Focus

This plan is deliberately ambitious. Delivering it means growing the people, structures and shared capability behind ALK Positive Australia, drawing more fully on our Executive Committee and our membership, so what today rests on a small number of people, becomes work carried by many. This section sets out how we intend to build on the capacity of ALK Positive Australia as the organisation continues to grow.



1. Executive and sub-committee capacity

- Establish Executive-led sub-committees e.g. **1. Research and Innovation, 2. Advocacy and Policy, 3. Awareness, 4. Community Connection and Support**, comprising members and led by Executive representatives to increase member involvement, harness the skills and expertise within our community, and share responsibility for delivering on the Strategic Plan across a wider group.
- Develop terms of reference for Executive and sub-committee positions, to support informed recruitment, involvement and sustainable participation.

Measure

- Number of active sub-committees established.
- Proportion of Executive members and members holding an active role.
- Terms of Reference developed and ratified by the Executive Committee.



2. Member engagement pipeline

- Create pathways for members to build their capabilities so the organisation's capacity grows with its membership base.
- Mentor and support any interested future Executive candidates.

Measure

- Number of members progressing into sub-committees or Executive roles.
- A strong and diverse pipeline of members is prepared and supported to take on future Executive and governance roles.



3. Succession and delegation

- Document key organisational knowledge and processes.
- Build a deliberate succession pathway for key Executive roles.

Measure

- Key roles and processes documented.
- Succession plan in place for identified key positions.

CLOSING STATEMENT

A note from our Deputy Chairperson

Over the past 12 months in my role as Deputy Chairperson of ALK Positive Australia, my approach has been simple – **our members must be heard, and their voices must matter.**

As an organisation representing a community living with a rare form of lung cancer, we have a responsibility to listen beyond the statistics, understand what matters in people's everyday lives and ensure those experiences help shape the decisions we make and the future we build. This belief was the driving force behind the development of the new strategic plan for ALK Positive Australia, which was supported and approved wholeheartedly by the Executive Committee. I wanted to create a meaningful opportunity for our members to tell us, in their own words, what matters most to them and what they want our organisation to stand for, prioritise and achieve in the years ahead.

I feel genuinely honoured to have since led the 2027 – 2030 Strategic Plan Subcommittee throughout this process. Over more than eight in-depth meetings, we worked collaboratively to translate our members' feedback into a shared direction, with **research, access, awareness** and **connection** emerging as key priorities.

I am deeply grateful to everyone who took the time to participate, share their perspectives and place their trust in me to lead this process. Your voices have helped shape this plan, and your contributions deserve to be reflected not only in the words on these pages, but in the actions that follow.

I would also like to sincerely thank the members of the Strategic Plan Subcommittee and Executive Committee for their commitment, thoughtful contributions and willingness to work together towards a shared vision.

It is now time to lead with purpose and turn shared priorities into lasting impact.

Let's do this!

LISA BRIGGS

*Deputy Chairperson
Chair, Strategic Plan Subcommittee
ALK Positive Australia Inc.*

ALK POSITIVE

AUSTRALIA



Contact Us

www.alkpositive.org.au

